Clinical trials: Advanced NSCLC
Solid Tumor, NSCLC
ERK Inhibitor JSI-1187 in Advanced Solid Tumors
JSI-1187-101 phase 1 study
- Conditions
- Solid Tumor, NSCLC, Melanoma
- Trial name
- NCT06239623
- Testing
- JSI-1187
- Where
- China
- Volunteers
- 60 people
- Sponsor
- JS InnoPharm, LLC
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Non Small Cell Lung Cancer
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced…
- Trial name
- NCT05060796
- Testing
- CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells
- Where
- China
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Solid Tumor, NSCLC
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
- Trial name
- NCT06816108
- Testing
- ONO-7428
- Where
- 15 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Non-Small Cell Lung Cancer
Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer
A comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly gemcitabine in elder patients (> 75) with previously untreated advanced non-small cell lung cancer.
- Trial name
- GEEP (NCT00881296)
- Testing
- gemcitabine and carboplatin, Gemcitabine
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Hamamatsu University
Lung Cancer
Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00425646
- Testing
- bevacizumab, imatinib mesylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Advanced Non-small Cell Lung Cancer
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II…
- Trial name
- NCT06585059
- Testing
- TQB2928 injection + Almonertinib Mesilate Tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
This is an international, multi-center, prospective, randomized, open-label Phase 3 clinical trial of the cancer stemness inhibitor napabucasin administered with weekly paclitaxel versus weekly paclitaxel alone in patients with…
- Trial name
- CanStem43L (NCT02826161)
- Testing
- Napabucasin, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Sumitomo Pharma America, Inc.
NSCLC
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC.
- Trial name
- NCT07697586
- Testing
- SKB264+SKB118
- Where
- 2 sites in China
- Volunteers
- 206 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
RATIONALE: Radiation therapy to the brain may be effective in preventing brain metastases in patients with advanced non-small cell lung cancer.
- Trial name
- NCT01158170
- Testing
- Prophylactic cranial irradiation, Erlotinib /Gefitinib
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Non Small Cell Lung Cancer, Lung Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread.
- Trial name
- ZEAL (NCT00418886)
- Testing
- Vandetanib, Pemetrexed
- Where
- 110 sites in United States, Argentina and 19 more
- Volunteers
- 698 people
- Sponsor
- Genzyme, a Sanofi Company
Lung Cancer, NSCLC
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-naïve patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung…
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV
- Trial name
- CUBIK (NCT04223596)
- Testing
- Brigatinib
- Where
- 15 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Fundación GECP
Advanced Non-small Cell Lung Cancer
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
A trial to evaluate the tolerability and efficacy of SHR-A1921 in combination with adbelizumab and SHR-8068 with or without carboplatin in patients with advanced non-small cell lung cancer
- Trial name
- NCT06434103
- Testing
- SHR-A1921；Adebrelimab；SHR-8068；carboplatin
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.
- Trial name
- NCT06797362
- Testing
- NVL-520
- Where
- 30 sites in Australia, Belgium and 8 more
- Sponsor
- Nuvalent Inc.
Non Small Cell Lung Cancer, Circulating Tumor Cell
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
clinical trial The goal of this clinical trial is to learn whether the treatment of advanced non-small cell lung cancer with EGFR-TKIs, when combined with bevacizumab in the presence of positive circulating tumor cells in the…
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- NCT06557096
- Testing
- Osimertinib 80 MG, Bevacizumab
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Nonsmall Cell Lung Cancer
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients with Advanced EGFRm+ NSCLC
- Trial name
- PRECENT (NCT02988141)
- Volunteers
- 100 people
- Sponsor
- Jianxing He
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This phase I trial tests the safety, side effects, and best dose of carfilzomib in combination with sotorasib in treating patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that may have spread from where it first…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06249282
- Testing
- Biopsy, Biospecimen Collection, Carfilzomib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Non Squamous Non Small Cell Lung Cancer
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed…
- Trial name
- NCT05841472
- Testing
- Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
- Where
- 8 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- CrystalGenomics, Inc.